<DOC>
	<DOCNO>NCT00890929</DOCNO>
	<brief_summary>This study phase 1 phase 2 component . In phase 1 , objective determine maximum tolerate dose ( MTD ) lenalidomide azacitidine . In phase 2 , objective determine efficacy combination treatment .</brief_summary>
	<brief_title>Phase 1-2 Azacitidine + Lenalidomide Previously Untreated Elderly Patients With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>The treatment regimen study 7 day course azacitidine 75 mg/m2 follow 21-day course lenalidomide . For primary objective , 28-day cycle repeat total 6 cycle . Study completion define 18 cycle treatment , disease progression , death . In phase 1 , objective determine maximum tolerate dose ( MTD ) lenalidomide 5 mg , 10 mg , 25 mg 50 mg , administer azacitidine . In phase 2 , objective ass efficacy MTD lenalidomide administer azacitidine , six 28-day cycle .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion Criteria WHOconfirmed acute myeloid leukemia ( AML ) , except acute promyelocytic leukemia ( APL ) White blood cell count ( WBC ) initiation treatment ≤ 10,000 ◦If WBC &gt; 10,000 patient may start appropriate dose hydroxyurea ( determined investigator ) , WBC &lt; 10,000 , time hydroxyurea discontinue 24 hour prior enrollment Age ≥ 60 year candidate allogeneic stem cell transplantation Unwilling unable receive conventional chemotherapy No prior therapy , except supportive care measure growth factor support , blood product transfusion , apheresis , hydroxyurea ECOG performance status ≤ 2 Life expectancy &gt; 2 month All study participant must register mandatory RevAssist® program , must willing able comply requirement RevAssist If female childbearing potential ( FCBP ) : Must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior study enrollment within 24 hour prescribe lenalidomide ( prescription must fill within 7 day ) Must commit either continued abstinence heterosexual intercourse begin two acceptable method birth control , one highly effective method one additional effective method time , least 28 day start lenalidomide . Must also agree ongoing pregnancy test . Male partner must use latex condom sexual contact , include male partner previously successful vasectomy . Able adhere study visit schedule protocol requirement Willing able understand voluntarily sign write informed consent Exclusion Criteria Relapsed refractory disease Prior therapy lenalidomide History intolerance thalidomide development erythema nodosum take thalidomide similar drug Known suspected hypersensitivity azacitidine mannitol Advanced malignant hepatic tumor Concomitant treatment antineoplastic agent , except hydroxyurea Antineoplastic treatment less four week prior enrollment , except hydroxyurea Use experimental drug therapy within 28 day baseline Inability swallow absorb drug Active opportunistic infection treatment opportunistic infection within four week first day study drug dose New York Heart Association Class III IV heart failure Unstable angina pectoris Uncontrolled cardiac arrhythmia Uncontrolled psychiatric illness would limit compliance requirement Known HIV infection If female : Pregnant Breastfeeding female , agree breastfeed take lenalidomide Other medical psychiatric illness organ dysfunction laboratory abnormality opinion investigator would compromise patient 's safety interfere data interpretation Laboratory abnormality : Creatinine ≥ 1.5 mg/dL Creatinine clearance ≤ 50 mL/min Total bilirubin &gt; 1.5 x institutional upper limit normal ( ULN ) , except document Gilbert 's syndrome AST &gt; 2.5 x institutional ULN ALT &gt; 2.5 x institutional ULN</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Acute myeloblastic leukemia</keyword>
	<keyword>AML</keyword>
</DOC>